Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Patients complience correlates to pharmacogenomics of drugs used in the treatment of early stage breast cancer (CROSBI ID 639133)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa

Bojanić, Kristina ; Kizivat, Tomislav ; Kuna, Lucija ; Wagner, Jasenka ; Smolić, Robert ; Bilić-Čurčić, Ines ; Kralik, Kristina ; Smolić, Martina, Tucak, Antun ; Včev, Aleksandar Patients complience correlates to pharmacogenomics of drugs used in the treatment of early stage breast cancer // IUAES - World anthropologies and privatization of knwoledge: engaing anthropology in public. 2016. str. xx-xx

Podaci o odgovornosti

Bojanić, Kristina ; Kizivat, Tomislav ; Kuna, Lucija ; Wagner, Jasenka ; Smolić, Robert ; Bilić-Čurčić, Ines ; Kralik, Kristina ; Smolić, Martina, Tucak, Antun ; Včev, Aleksandar

engleski

Patients complience correlates to pharmacogenomics of drugs used in the treatment of early stage breast cancer

Anastrozole is a selective competitive aromatase inhibitor (AI) widely used as adjuvant treatment for early stage breast cancer. Highly efficient estrogen depletion by AI benefits breast cancer (BC) patients by extending recurrence-free survival. However, AIs put patients at high risk of osteoporosis due to the central role of estrogen in maintaining normal bone metabolism. Although awareness of osteoporosis by health care professionals has increased in recent years, it remains underdiagnosed and undertreated. Findings of this study should raise awarness of the importance of BMD screening among BC patients treated with anastrazole and to tailor treatment and prevention strategies for Al users as a high - risk population for bone morbidity. The intensity of adverse effects plays an essential part in maintaining patient complience to anastrazole therapy. Functional genetic polymorphisms of enzymes involved in anastrazole metabolism could be correlated to altered aromatase activity, disease prognosis and severity of aromatase inhibitor adverse effects, however large genotyping studies are obligatory.

pharmacogenetics ; breast cancer ; aromatase inhibitor ; adverse drug reactions ; osteoporosis ; hepatotoxicty

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

xx-xx.

2016.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

IUAES - World anthropologies and privatization of knwoledge: engaing anthropology in public

Podaci o skupu

IUAES - World anthropologies and privatization of knwoledge: engaing anthropology in public

poster

04.05.2016-09.05.2016

Dubrovnik, Hrvatska

Povezanost rada

Temeljne medicinske znanosti